초록 ▼

A mounting arrangement facilitates mounting and removal of an article, such as an elongated housing for a proximity sensor. A bracket and a coupling each have an aperture extending therethrough for receiving the article. A central axis extends through the apertures. The coupling includes a plurality

A mounting arrangement facilitates mounting and removal of an article, such as an elongated housing for a proximity sensor. A bracket and a coupling each have an aperture extending therethrough for receiving the article. A central axis extends through the apertures. The coupling includes a plurality of spaced apart flexures located adjacent the coupling aperture. Each flexure includes an axially extending arm portion for engaging a respective part of an inner sidewall portion of the bracket aperture. Upon rotation of the coupling about the central axis, the bracket sidewall portion engages or releases the arms of the coupling to effect radial movement of the arms. In particular, rotation of the coupling in one direction about the central axis relative to the bracket urges the arms radially inward and rotation of the coupling in the other direction permits a radially outward movement thereof.

대표청구항 ▼

A mounting arrangement facilitates mounting and removal of an article, such as an elongated housing for a proximity sensor. A bracket and a coupling each have an aperture extending therethrough for receiving the article. A central axis extends through the apertures. The coupling includes a plurality

A mounting arrangement facilitates mounting and removal of an article, such as an elongated housing for a proximity sensor. A bracket and a coupling each have an aperture extending therethrough for receiving the article. A central axis extends through the apertures. The coupling includes a plurality of spaced apart flexures located adjacent the coupling aperture. Each flexure includes an axially extending arm portion for engaging a respective part of an inner sidewall portion of the bracket aperture. Upon rotation of the coupling about the central axis, the bracket sidewall portion engages or releases the arms of the coupling to effect radial movement of the arms. In particular, rotation of the coupling in one direction about the central axis relative to the bracket urges the arms radially inward and rotation of the coupling in the other direction permits a radially outward movement thereof. weight ratio to the antidiabetic agent within the range from about 0.01 to about 300:1. 9. The combination as defined in claim 4 wherein the anti-obesity agent is a beta 3 adrenergic agonist, a lipase inhibitor, a serotonin (and dopamine) reuptake inhibitor, a thyroid receptor beta compound, and/or an anorectic agent. 10. The combination as defined in claim 9 wherein the anti-obesity agent is orlistat, ATL-962, AJ9677, L750355, CP331648, sibutramine, topiramate, axokine, dexamphetamine, phentermine, phenylpropanolamine, and/or mazindol. 11. The combination as defined in claim 4 wherein the lipid lowering agent is an MTP inhibitor, an HMG CoA reductase inhibitor, a squalene synthetase inhibitor, a fibric acid derivative, an upregulator of LDL receptor activity, a lipoxygenase inhibitor, or an ACAT inhibitor. 12. The combination as defined in claim 11 wherein the lipid lowering agent is pravastatin, lovastatin, simvastatin, atorvastatin, cerivastatin, fluvastatin, nisvastatin, visastatin, atavastatin, rosuvastatin, fenofibrate, gemfibrozil, clofibrate, avasimibe, TS-962, MD-700, and/or LY295427. 13. The combination as defined in claim 11 wherein the SGLT2 inhibitor is present in a weight ratio to the lipid-lowering agent within the range from about 0.01 to about 300:1. 14. A method for treating or delaying the progression or onset of diabetes, diabetic retinopathy, diabetic neuropathy, diabetic nephropathy, delayed wound healing, insulin resistance, hyperglycemia, hyperinsulinemia, elevated blood levels of fatty acids or glycerol, hyperlipidemia, obesity, hypertriglyceridemia, Syndrome X, diabetic complications, atherosclerosis or hypertension, or for increasing high density lipoprotein levels, which comprises administering to a mammalian species in need of treatment a therapeutically effective amount of a compound as defined in claim 1. 15. The method as defined in claim 14 where the SGLT2 inhibitor compound has the structure 16. A method for treating type II diabetes which comprises administering to a mammalian species in need of treatment a therapeutically effective amount of a compound as defined in claim 1 alone or in combination with another antidiabetic agent, an agent for treating the complications of diabetes, an anti-obesity agent, an antihypertensive agent, an antiplatelet agent, an anti-atherosclerotic agent and/or a hypolipidemic agent. 17. A compound having the structure or a pharmaceutically acceptable salt thereof, all stereolsomers thereof, or a prodrug ester thereof. an expression vector according to claim 3 into a host cell or cellular extract, incubating said host cell or extract under conditions whereby said polypeptide is expressed as a translation product of said expression vector, and isolating said polypeptide. 10. A polynucleotide consisting of 24 consecutive nucleotides of SEQ ID NO:1. 11. A polynucleotide consisting of 36 consecutive nucleotides of SEQ ID NO:1. 12. A polynucleotide consisting of 96 consecutive nucleotides of SEQ ID NO:1. 13. An isolated, recombinant polynucleotide comprising a sequence selected from the group consisting of: nucleotides 113-463, nucleotides 464-784, and nucleotides 785-1105 of SEQ ID NO:1. 14. An isolated, recombinant polynucleotide according to claim 13, wherein the sequence comprises SEQ ID NO:1. 15. An isolated, recombinant expression vector according to claim 1, consisting of a sequence encoding 10, 12 or 14 consecutive amino acid residues of SEQ ID NO:2. 16. An isolated, recombinant expression vector according to claim 1, wherein the sequence encodes a fragment of SEQ ID NO:2 selected from the group consisting of: residues 1-117, residues 118-224 and residues 225-331. 17. A cell comprising an expression vector according to claim 16. 18. A method of making a polypeptide, comprising steps: introducing an expression vector according to claim 16 into a host cell or cellular extract, incubating said host cell or extract under conditions whereby said polypeptide is expressed as a translation product of said expression vector, and isolating said polypeptide.